Celyad Oncology (CYAD) H1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
H1 2025 earnings summary
25 Sep, 2025Executive summary
Reported first half 2025 financial results, with a treasury position of €0.8 million as of June 30, 2025.
Cash and cash equivalents projected to fund operations into Q4 2025 based on current forecasts.
Financial highlights
Revenue for H1 2025 was €0.2 million, unchanged from H1 2024.
Net loss for H1 2025 was €3.7 million (€0.09 per share), compared to €3.0 million (€0.07 per share) in H1 2024.
Net cash used in operations increased to €3.3 million in H1 2025 from €2.8 million in H1 2024.
No capital increase occurred in H1 2025; 41.4 million shares outstanding.
Outlook and guidance
Existing cash and cash equivalents expected to cover estimated operating and capital expenditures into Q4 2025.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Celyad Oncology
- Returned to profitability in 2025 via asset sales, but future depends on IP monetization and new funding.CYAD
H2 20252 Apr 2026 - Net loss narrowed and cash runway secured as CAR T-cell platforms advance and partnerships pursued.CYADH1 202413 Jun 2025
- Net loss narrowed and cash burn reduced as Celyad advanced CAR-T platforms but faces funding risks.CYADH2 20246 Jun 2025